Synopsis
Synopsis
0
EU WC
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Gamma L Glu L Cys Gly
2. Gamma L Glutamyl L Cysteinylglycine
3. Gamma-l-glu-l-cys-gly
4. Gamma-l-glutamyl-l-cysteinylglycine
5. Glutathione, Reduced
6. Reduced Glutathione
1. 70-18-8
2. L-glutathione
3. Glutathion
4. Isethion
5. L-glutathione Reduced
6. Tathion
7. Reduced Glutathione
8. Glutathione-sh
9. Glutinal
10. Tathione
11. Deltathione
12. Neuthion
13. Copren
14. Glutide
15. Triptide
16. Ledac
17. Gsh
18. Glutatione
19. Glutatiol
20. Glutathione Reduced
21. Panaron
22. Glutathione Sh
23. L-glutatione
24. Agifutol S
25. Glutathione (reduced)
26. L-gamma-glutamyl-l-cysteinylglycine
27. Gamma-l-glutamyl-l-cysteinylglycine
28. Glutathione [jan]
29. L-glutathione, Reduced
30. Gamma-l-glutamyl-l-cysteinyl-glycine
31. 5-l-glutamyl-l-cysteinylglycine
32. Glutham
33. Gamma-l-glutamylcysteinylglycine
34. Glutathione Red
35. Aec Glutathione
36. Red. Glutathione
37. Bakezyme Rx
38. L-glutathione Reduce
39. Glycine, L-gamma-glutamyl-l-cysteinyl-
40. Reduced L-glutathione
41. (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic Acid
42. (s)-2-amino-5-(((r)-1-((carboxymethyl)amino)-3-mercapto-1-oxopropan-2-yl)amino)-5-oxopentanoic Acid
43. N-(n-gamma-l-glutamyl-l-cysteinyl)glycine
44. N-(n-l-gamma-glutamyl-l-cysteinyl)glycine
45. Glycine, N-(n-l-gamma-glutamyl-l-cysteinyl)-
46. Gan16c9b8o
47. L-glutamyl-l-cysteinylglycine
48. L-glutathione (reduced Form)
49. Glycine, L-.gamma.-glutamyl-l-cysteinyl-
50. Benzenamine, 2-[(4-methoxyphenyl)methoxy]-
51. Chebi:16856
52. (2s)-2-amino-4-{[(1r)-1-[(carboxymethyl)carbamoyl]-2-sulfanylethyl]carbamoyl}butanoic Acid
53. 106272-20-2
54. 95687-20-0
55. Dsstox_cid_3101
56. N-(n-l-.gamma.-glutamyl-l-cysteinyl)glycine
57. N5-((r)-1-((carboxymethyl)amino)-3-mercapto-1-oxopropan-2-yl)-l-glutamine
58. Dsstox_rid_76875
59. Dsstox_gsid_23101
60. [glu(-cys)]n-gly
61. Mfcd00065939
62. Cas-70-18-8
63. (s)-2-amino-5-((r)-1-(carboxymethylamino)-3-mercapto-1-oxopropan-2-ylamino)-5-oxopentanoic Acid
64. Glutathione, Reduced
65. Ccris 2094
66. Sr-05000002567
67. Glutathione [ban:jan]
68. Einecs 200-725-4
69. L-glutathione Reduced Form
70. Unii-gan16c9b8o
71. Nsc 400639
72. Phytochelatins
73. Readisorb
74. Glutathione;
75. Nsc400639
76. 1lbk
77. Ncgc00094976-01
78. Tathion (tn)
79. Glutathione (jp17)
80. Spectrum_000419
81. 1oe7
82. 1oe8
83. 1r4w
84. C(n-.gamma.glu-)g
85. Glutathione [ii]
86. Glutathione [mi]
87. Reduced Glutathione,(s)
88. Spectrum2_001500
89. Spectrum3_000946
90. Spectrum4_001056
91. Spectrum5_000940
92. Glutathione, Reduced Form
93. Glutathione [inci]
94. Bmse000185
95. Bmse000952
96. Bmse000956
97. Glutathione (reduced Type)
98. Glutathione [vandf]
99. Cys(n-.gamma.glu-)-gly
100. Schembl9167
101. Chembl1543
102. Glutathione [mart.]
103. Glutathione [usp-rs]
104. Glutathione [who-dd]
105. Kbiogr_001352
106. Kbioss_000899
107. Mls001333069
108. Divk1c_000075
109. Spectrum1502248
110. Spbio_001519
111. Gamma-glutamyl-cysteinyl-glycine
112. Gtpl6737
113. Dtxsid6023101
114. L-?-glutamyl-l-cysteinylglycine
115. L-glutathione Reduced, 97.0%
116. Chebi:60836
117. Hms500d17
118. Kbio1_000075
119. Kbio2_000899
120. Kbio2_003467
121. Kbio2_006035
122. Kbio3_002012
123. (gamma-glutamylcysteine)n-glycine
124. L-g-glutamyl-l-cysteinyl-glycine
125. Y-l-glutamyl-l-cysteinyl-glycine
126. L-?-glutamyl-l-cysteinyl-glycine
127. Ninds_000075
128. Glutathione [ep Monograph]
129. Hms1921n22
130. Pharmakon1600-01502248
131. Poly(gamma-glutamylcysteine)glycine
132. Hy-d0187
133. L-glutathione Reduced, >=98.0%
134. Zinc3830891
135. Gam.-l-glutamyl-l-cysteinyl-glycine
136. Tox21_111371
137. Bdbm50422268
138. Ccg-38876
139. L-gamma-glutamyl-l-cysteinyl-glycine
140. Nsc758199
141. S4606
142. Akos015999135
143. Tox21_111371_1
144. Cs-7948
145. Db00143
146. Nsc-758199
147. Sdccgmls-0066687.p001
148. .gamma.-l-glutamyl-l-cysteinyl-glycine
149. Idi1_000075
150. N-(n-l-?-glutamyl-l-cysteinyl)glycine
151. Pharm Biol 11: 539 (1968)
152. Smp1_000247
153. Ncgc00264046-02
154. Ds-14675
155. Gsh;gamma-l-glutamyl-l-cysteinyl-glycine
156. Smr000857220
157. Sbi-0051743.p002
158. L-glutathione Reduced, Bioxtra, >=98.0%
159. B7775
160. G0074
161. Glycine, N-(n-l-gamma-glutamyl-l-cysteinyl)
162. C00051
163. C02471
164. D00014
165. G-3980
166. P19615
167. Ab00443568_03
168. Glutathione 100 Microg/ml In Acetonitrile:water
169. A866658
170. Q116907
171. Sr-05000002567-1
172. Sr-05000002567-2
173. L-glutathione Reduced, Vetec(tm) Reagent Grade, >=98%
174. Z2183947556
175. Glutathione, European Pharmacopoeia (ep) Reference Standard
176. Glutathione, United States Pharmacopeia (usp) Reference Standard
177. Glutathione, Pharmaceutical Secondary Standard; Certified Reference Material
178. L-glutathione Reduced, Cell Culture Tested, Bioreagent, >=98.0%, Powder
179. (2s)-2-amino-4-{[(1r)-1-[(carboxymethyl)carbamoyl]-2-sulfanylethyl]carbamoylbutanoic Acid
180. (2s)-2-amino-5-({(2r)-1-[(carboxymethyl)amino]-1-oxo-3-sulfanyl-2-propanyl}amino)-5-oxopentanoic Acid
181. Glutathione; L-glutathione Reduced; 5-l-glutamyl-l-cysteinylglycine; Gamma-l-glutamyl-l-cysteinylglycine; Gsh
| Molecular Weight | 307.33 g/mol |
|---|---|
| Molecular Formula | C10H17N3O6S |
| XLogP3 | -4.5 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 9 |
| Exact Mass | 307.08380644 g/mol |
| Monoisotopic Mass | 307.08380644 g/mol |
| Topological Polar Surface Area | 160 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 389 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For nutritional supplementation, also for treating dietary shortage or imbalance
V - Various
V03 - All other therapeutic products
V03A - All other therapeutic products
V03AB - Antidotes
V03AB32 - Glutathione
Absorption
Research suggests that glutathione is not orally bioactive, and that very little of oral glutathione tablets or capsules is actually absorbed by the body.
Glutathione (GSH) participates in leukotriene synthesis and is a cofactor for the enzyme glutathione peroxidase. It also plays a role in the hepatic biotransformation and detoxification process; it acts as a hydrophilic molecule that is added to other lipophilic toxins or wastes prior to entering biliary excretion. It participates in the detoxification of methylglyoxal, a toxic by-product of metabolism, mediated by glyoxalase enzymes. Glyoxalase I catalyzes the conversion of methylglyoxal and reduced glutathione to S-D-Lactoyl-glutathione. Glyoxalase II catalyzes the conversion of S-D-Lactoyl Glutathione to Reduced Glutathione and D-lactate. Glyoxalase I catalyzes the conversion of methylglyoxal and reduced glutathione to S-D-Lactoyl-glutathione. Glyoxalase II catalyzes the conversion of S-D-Lactoyl Glutathione to Reduced Glutathione and D-lactate. GSH is a cofactor of conjugation and reduction reactions that are catalyzed by glutathione S-transferase enzymes expressed in the cytosol, microsomes, and mitochondria. However, it is capable of participating in non-enzymatic conjugation with some chemicals, as it is hypothesized to do to a significant extent with n-acetyl-p-benzoquinone imine (NAPQI), the reactive cytochrome P450 reactive metabolite formed by toxic overdose of acetaminophen. Glutathione in this capacity binds to NAPQI as a suicide substrate and in the process detoxifies it, taking the place of cellular protein sulfhydryl groups which would otherwise be toxically adducted. The preferred medical treatment to an overdose of this nature, whose efficacy has been consistently supported in literature, is the administration (usually in atomized form) of N-acetylcysteine, which is used by cells to replace spent GSSG and allow a usable GSH pool.
API SUPPLIERS
Bioquim: An European GMP-certified company manufacturing bulk APIs, specializing in sterile lyophilization and chemical synthesis.
Basic Nutrition, your expert for sourcing from China, India and Europe.
Mesochem is focused on incessant innovation along with the R&D of new APIs.
Sumar Biotech work together to Innovate & Manufacture Semi-synthetic, Synthetic & Fermentation API.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7799
Submission : 1988-12-02
Status : Active
Type : II
Certificate Number : R0-CEP 2020-328 - Rev 00
Issue Date : 2023-01-13
Type : Chemical
Substance Number : 1670
Status : Valid
Registration Number : 217MF10240
Registrant's Address : 1-6-1 Otemachi, Chiyoda-ku, Tokyo
Initial Date of Registration : 2005-06-15
Latest Date of Registration :
NDC Package Code : 12497-1054
Start Marketing Date : 1988-12-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2562
Submission : 1975-11-13
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3068
Submission : 1977-11-09
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3043
Submission : 1977-10-21
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4278
Submission : 1981-09-17
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8893
Submission : 1990-12-17
Status : Inactive
Type : II
Certificate Number : R0-CEP 2014-174 - Rev 00
Issue Date : 2016-06-09
Type : Chemical
Substance Number : 1670
Status : Withdrawn by Holder
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2562
Submission : 1975-11-13
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3068
Submission : 1977-11-09
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8893
Submission : 1990-12-17
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7799
Submission : 1988-12-02
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4278
Submission : 1981-09-17
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3043
Submission : 1977-10-21
Status : Inactive
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37051
Submission : 2024-12-03
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
Certificate Number : R0-CEP 2020-328 - Rev 00
Status : Valid
Issue Date : 2023-01-13
Type : Chemical
Substance Number : 1670
Certificate Number : R0-CEP 2014-174 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2016-06-09
Type : Chemical
Substance Number : 1670
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] JDMF
Japanese Pharmacopoeia Glutathione
Registration Number : 217MF10303
Registrant's Address : 1-1-3 Yurakucho, Chiyoda-ku, Tokyo
Initial Date of Registration : 2005-06-30
Latest Date of Registration : 2010-03-02
Registration Number : 217MF10240
Registrant's Address : 1-6-1 Otemachi, Chiyoda-ku, Tokyo
Initial Date of Registration : 2005-06-15
Latest Date of Registration : 2014-12-08
Registration Number : 223MF10160
Registrant's Address : Zichuan Economic Development Zone, Zibo City, Shandong Province, China
Initial Date of Registration : 2011-11-14
Latest Date of Registration : 2011-11-14
Glutathione (pharmaceutical intermediate)
Registration Number : 304MF10007
Registrant's Address : Zichuan Economic Development Zone, Zibo City, Shandong Province, China
Initial Date of Registration : 2022-01-11
Latest Date of Registration : 2022-01-11
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]KDMF
Registrant Name : (주)에스지바이오켐
Registration Date : 2021-08-27
Registration Number : 20200629-211-J-663(1)
Manufacturer Name : Shandong Jincheng Bio-pharma...
Manufacturer Address : Jiao Wang Fu Xian Road North, Dong Yi Road West, Zichuan Economy Development Zone, Zi...
Registrant Name : Hiple Co., Ltd.
Registration Date : 2020-06-29
Registration Number : 20200629-211-J-663
Manufacturer Name : Shandong Jin cheng Bio-Pharm...
Manufacturer Address : Jiao Wang Fu Xian Road North, Dong Yi Road West, Zichuan Economy Development Zone, Zi...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
ARINA-1 is a new nebulized product comprising ascorbic acid, glutathione, and bicarbonate, currently investigated in phase 2 trials for treating Non-cystic Fibrosis Bronchiectasis.
Lead Product(s): Ascorbic Acid,Bicarbonate,Glutathione
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: ARINA-1
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 01, 2024
Lead Product(s) : Ascorbic Acid,Bicarbonate,Glutathione
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Renovion Completes Enrollment of Adult Patients in Phase 2 CLIMB Study in Bronchiectasis
Details : ARINA-1 is a new nebulized product comprising ascorbic acid, glutathione, and bicarbonate, currently investigated in phase 2 trials for treating Non-cystic Fibrosis Bronchiectasis.
Product Name : ARINA-1
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
November 01, 2024
Details:
INJA Glow (glutathione) is an extremely poweful antioxidant, small molecule drug candidate, which is indicated for the treatment of acne and scars.
Lead Product(s): Glutathione
Therapeutic Area: Dermatology Brand Name: INJA Glow
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 16, 2024
Lead Product(s) : Glutathione
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
INJA Wellness Launches India's First Liposomal Glutathione Effervescent Tablets
Details : INJA Glow (glutathione) is an extremely poweful antioxidant, small molecule drug candidate, which is indicated for the treatment of acne and scars.
Product Name : INJA Glow
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 16, 2024
Details:
ARINA-1 is a new nebulized product composed of ascorbic acid, glutathione, and bicarbonate, currently in phase 2 trials for treating patients with Non-cystic Fibrosis Bronchiectasis.
Lead Product(s): Ascorbic Acid,Bicarbonate,Glutathione
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: ARINA-1
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 30, 2024
Lead Product(s) : Ascorbic Acid,Bicarbonate,Glutathione
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Renovion Reports Positive Results from Phase 2 CLIMB Study of ARINA-1
Details : ARINA-1 is a new nebulized product composed of ascorbic acid, glutathione, and bicarbonate, currently in phase 2 trials for treating patients with Non-cystic Fibrosis Bronchiectasis.
Product Name : ARINA-1
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 30, 2024
Details:
DuraGraft is a first-in-class CE marked intra-operative graft storage solution used during bypass surgeries that is authorized for use in Europe and other countries outside of the United States.
Lead Product(s): Glutathione,Ascorbic Acid
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: DuraGraft
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 10, 2023
Lead Product(s) : Glutathione,Ascorbic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™
Details : DuraGraft is a first-in-class CE marked intra-operative graft storage solution used during bypass surgeries that is authorized for use in Europe and other countries outside of the United States.
Product Name : DuraGraft
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2023
Details:
ARINA-1 (ascorbic acid) is an investigational nebulized therapy to prevent the progression of bronchiolitis obliterans syndrome (BOS) progression in individuals with a bilateral lung transplant.
Lead Product(s): Ascorbic Acid,Glutathione
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: ARINA-1
Study Phase: Phase IIIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 18, 2023
Lead Product(s) : Ascorbic Acid,Glutathione
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Details : ARINA-1 (ascorbic acid) is an investigational nebulized therapy to prevent the progression of bronchiolitis obliterans syndrome (BOS) progression in individuals with a bilateral lung transplant.
Product Name : ARINA-1
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 18, 2023
Details:
USPTO has granted a patent to Mitsubishi Corporation Life Sciences for a method of improving nonalcoholic fatty liver disease in patients in need of treatment, comprising the administration of a composition containing glutathione as its active ingredient.
Lead Product(s): Glutathione
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Opitac
Study Phase: UndisclosedProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 21, 2022
Lead Product(s) : Glutathione
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : USPTO has granted a patent to Mitsubishi Corporation Life Sciences for a method of improving nonalcoholic fatty liver disease in patients in need of treatment, comprising the administration of a composition containing glutathione as its active ingredient...
Product Name : Opitac
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2022
Details:
ARINA-1 (ascorbic acid), an investigational nebulized therapy, to treat adults with non-CF bronchiectasis,has been shown to have significant mucolytic activity, as well as robust anti-inflammatory properties.
Lead Product(s): Ascorbic Acid,Glutathione
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: ARINA-1
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 11, 2022
Lead Product(s) : Ascorbic Acid,Glutathione
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ARINA-1 (ascorbic acid), an investigational nebulized therapy, to treat adults with non-CF bronchiectasis,has been shown to have significant mucolytic activity, as well as robust anti-inflammatory properties.
Product Name : ARINA-1
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 11, 2022
Details:
The paper provides an overview of the impact of ARINA-1 on mucus transport and shows that the ARINA-1 moves mucus significantly better than currently available options in cystic fibrosis (CF).
Lead Product(s): Ascorbic Acid,Bicarbonate,Glutathione
Therapeutic Area: Genetic Disease Brand Name: ARINA-1
Study Phase: PreclinicalProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 07, 2020
Lead Product(s) : Ascorbic Acid,Bicarbonate,Glutathione
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The paper provides an overview of the impact of ARINA-1 on mucus transport and shows that the ARINA-1 moves mucus significantly better than currently available options in cystic fibrosis (CF).
Product Name : ARINA-1
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
September 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : DISCN
Registration Country : USA
CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
Brand Name : METHOTREXATE SODIUM
Dosage Form : SOLUTION;IRRIGATION
Dosage Strength : 0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML
Packaging :
Approval Date : 1999-02-26
Application Number : 20079
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Effervescent Tablet
Dosage Strength : 500MG; 80MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 600MG/Vial
Packaging : 10 ml
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name : Themiglu
Dosage Form : Injection
Dosage Strength : 600MG
Packaging : 1x600
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : Generic
Registration Country : Turkey
Brand Name :
Dosage Form : INJECTABLE
Dosage Strength : 2500MG/25ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Turkey
Regulatory Info :
Registration Country : Turkey
Brand Name : RAM 600
Dosage Form : LYOPHILISED POWDER FOR INJECTABLE
Dosage Strength : 600MG/4ML
Packaging : 10 VIALS + 10 SOLVENTS(WFI)
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Turkey
Regulatory Info :
Registration Country : Italy
Brand Name : Ridutox
Dosage Form :
Dosage Strength : 10 Vials Im Ev 600 Mg + 10 Vials Solv 4 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Glutathione
Dosage Form :
Dosage Strength : 10 Vials Im Ev 600 Mg + 10 Vials Solv 4 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Tad 600
Dosage Form :
Dosage Strength : 10 Vials Im Ev 600 Mg + 10 Vials Solv 4 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
RLD : Yes
TE Code :
CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
Brand Name : BSS PLUS
Dosage Form : SOLUTION;IRRIGATION
Dosage Strength : 0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML
Approval Date : 1982-01-01
Application Number : 18469
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : No
TE Code :
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
Brand Name : NAVSTEL
Dosage Form : SOLUTION;IRRIGATION
Dosage Strength : 0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML
Approval Date : 2008-07-24
Application Number : 22193
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
Brand Name : METHOTREXATE SODIUM
Dosage Form : SOLUTION;IRRIGATION
Dosage Strength : 0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML
Approval Date : 1999-02-26
Application Number : 20079
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Dossiers
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 5MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Vial
Dosage Strength : 600MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Vial
Dosage Strength : 600MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Effervescent Tablet
Dosage Strength : 500MG; 80MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Effervescent Tablet
Dosage Strength : 500MG; 80MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 600MG/Vial
Packaging : 10 ml
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging : 10 ml
Regulatory Info :
Dosage : Injection
Dosage Strength : 600MG/Vial
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 600MG
Packaging : 10 ml
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging : 10 ml
Regulatory Info :
Dosage : Injection
Dosage Strength : 600MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 500MG; 80MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 500MG; 80MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name : Themiglu
Dosage Form : Injection
Dosage Strength : 600MG
Packaging : 1x600
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging : 1x600
Regulatory Info :
Dosage : Injection
Dosage Strength : 600MG
Brand Name : Themiglu
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : Turkey
Brand Name : RAM 600
Dosage Form : LYOPHILISED POWDER FOR...
Dosage Strength : 600MG/4ML
Packaging : 10 VIALS + 10 SOLVENTS(WFI)
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Turkey
Packaging : 10 VIALS + 10 SOLVENTS(WFI)
Regulatory Info :
Dosage : LYOPHILISED POWDER FOR...
Dosage Strength : 600MG/4ML
Brand Name : RAM 600
Approval Date :
Application Number :
Registration Country : Turkey
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Thickeners and Stabilizers
Parenteral
Direct Compression
Co-Processed Excipients
Granulation
Taste Masking
Coating Systems & Additives
Disintegrants & Superdisintegrants
Controlled & Modified Release
Topical
Film Formers & Plasticizers
Solubilizers
Chewable & Orodispersible Aids
API Stability Enhancers
Rheology Modifiers
Lubricants & Glidants
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
APIs
Reply
31 Dec 2024
Reply
07 Sep 2024
Reply
19 Oct 2023
Reply
17 Jul 2023
Reply
11 Jul 2023
Reply
10 May 2023
Reply
24 Jan 2023
Reply
24 Sep 2022
Reply
08 Apr 2022
Reply
17 Mar 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
69
PharmaCompass offers a list of Glutathione API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Glutathione manufacturer or Glutathione supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Glutathione manufacturer or Glutathione supplier.
PharmaCompass also assists you with knowing the Glutathione API Price utilized in the formulation of products. Glutathione API Price is not always fixed or binding as the Glutathione Price is obtained through a variety of data sources. The Glutathione Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A L-Glutathione manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of L-Glutathione, including repackagers and relabelers. The FDA regulates L-Glutathione manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. L-Glutathione API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of L-Glutathione manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A L-Glutathione supplier is an individual or a company that provides L-Glutathione active pharmaceutical ingredient (API) or L-Glutathione finished formulations upon request. The L-Glutathione suppliers may include L-Glutathione API manufacturers, exporters, distributors and traders.
click here to find a list of L-Glutathione suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A L-Glutathione DMF (Drug Master File) is a document detailing the whole manufacturing process of L-Glutathione active pharmaceutical ingredient (API) in detail. Different forms of L-Glutathione DMFs exist exist since differing nations have different regulations, such as L-Glutathione USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A L-Glutathione DMF submitted to regulatory agencies in the US is known as a USDMF. L-Glutathione USDMF includes data on L-Glutathione's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The L-Glutathione USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of L-Glutathione suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The L-Glutathione Drug Master File in Japan (L-Glutathione JDMF) empowers L-Glutathione API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the L-Glutathione JDMF during the approval evaluation for pharmaceutical products. At the time of L-Glutathione JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of L-Glutathione suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a L-Glutathione Drug Master File in Korea (L-Glutathione KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of L-Glutathione. The MFDS reviews the L-Glutathione KDMF as part of the drug registration process and uses the information provided in the L-Glutathione KDMF to evaluate the safety and efficacy of the drug.
After submitting a L-Glutathione KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their L-Glutathione API can apply through the Korea Drug Master File (KDMF).
click here to find a list of L-Glutathione suppliers with KDMF on PharmaCompass.
A L-Glutathione CEP of the European Pharmacopoeia monograph is often referred to as a L-Glutathione Certificate of Suitability (COS). The purpose of a L-Glutathione CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of L-Glutathione EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of L-Glutathione to their clients by showing that a L-Glutathione CEP has been issued for it. The manufacturer submits a L-Glutathione CEP (COS) as part of the market authorization procedure, and it takes on the role of a L-Glutathione CEP holder for the record. Additionally, the data presented in the L-Glutathione CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the L-Glutathione DMF.
A L-Glutathione CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. L-Glutathione CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of L-Glutathione suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing L-Glutathione as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for L-Glutathione API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture L-Glutathione as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain L-Glutathione and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a L-Glutathione NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of L-Glutathione suppliers with NDC on PharmaCompass.
L-Glutathione Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of L-Glutathione GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right L-Glutathione GMP manufacturer or L-Glutathione GMP API supplier for your needs.
A L-Glutathione CoA (Certificate of Analysis) is a formal document that attests to L-Glutathione's compliance with L-Glutathione specifications and serves as a tool for batch-level quality control.
L-Glutathione CoA mostly includes findings from lab analyses of a specific batch. For each L-Glutathione CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
L-Glutathione may be tested according to a variety of international standards, such as European Pharmacopoeia (L-Glutathione EP), L-Glutathione JP (Japanese Pharmacopeia) and the US Pharmacopoeia (L-Glutathione USP).
Comment (6)
